National Comprehensive Cancer Network



About NCCN

NCCN Updates: Guidelines, Drugs & Biologics, Order Templates

NCCN Clinical Practice Guidelines in Oncology® for Myelodysplastic Syndromes Updated

The NCCN Clinical Practice Guidelines in Oncology® for Myelodysplastic Syndromes (MDS) have been updated and published by the National Comprehensive Cancer Network. The current version is 1.2010.  In the updated version, the category of evidence and consensus for recommending azacytidine for the treatment of higher risk MDS patients (IPSS risk category INTERMEDIATE-2 and High) is now Category 1. Previously, this recommendation was Category 2A. Updates also include the addition of azacytidine, decitabine, or participation in a clinical trial as recommended options for higher risk patients who relapse following allogeneic hemopoietic stem cell transplant.

 

NCCN Clinical Practice Guidelines in Oncology® for Cancer- and Chemotherapy- Induced Anemia Updated

The current version of the NCCN Guidelines for Cancer- and Chemotherapy- Induced Anemia is now v.1.2010. Updates included reference to new meta-analyses that further confirmed increased mortality risks associated with ESAs and treatment recommendations for no iron deficiency in asymptomatic patients with risk factors for developing anemia.

For the complete updated version of the NCCN Clinical Practice Guidelines in Oncology®, the NCCN Drugs & Biologics Compendium®, and the NCCN Chemotherapy Order Templates® please visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved